Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
Climb Bio, Inc. (CLYM)
Company Research
Source: GlobeNewswire
WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from October 23-27, 2024. Poster Presentation A Phase 1b Single Arm Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced ADCC, in Primary Membranous NephropathyPresenter: Frank Cortazar, M.D., Director, New York Nephrology Vasculitis and Glomerular Center;Chief, Division of Nephrology, St. Peter's Hospital; Chief, Clinical Research, St. Peter's Health Partners;Clinical Scientist, Massachusetts General HospitalSession Title: Membranous Nephropathy, FSGS, and Minimal Change Disease [PO1402-1] Session Date, Time: October 24, 2024 from 10:00 a.m. to 12:00 p.m. PTPoster Board #: TH-PO587 About Climb Bio, Inc. Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s
Show less
Read more
Impact Snapshot
Event Time:
CLYM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLYM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLYM alerts
High impacting Climb Bio, Inc. news events
Weekly update
A roundup of the hottest topics
CLYM
News
- Climb Bio to be Added to the Nasdaq Biotechnology IndexGlobeNewswire
- Climb Bio, Inc. (NASDAQ: CLYM) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Climb Bio, Inc. (NASDAQ: CLYM) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $10.00 price target on the stock.MarketBeat
- Climb Bio Reports Third Quarter 2024 Financial Results and Business HighlightsGlobeNewswire
- Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the BoardGlobeNewswire
CLYM
Analyst Actions
- 12/2/24 - Leerink Partners